Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB StudyValentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Journal of Clinical Oncology|2012Cited by 368
Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer PatientsToni Ibrahim, Dino Amadori, Emanuele Sacanna et al.|Clinical Breast Cancer|2011Cited by 50
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective StudySara Gagno, Giuseppe Toffoli, Marcella Montico et al.|Clinical Breast Cancer|2018Cited by 10